Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HS-10390 in Chronic Kidney Disease
NCT07555054Phase 2Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10390 in chronic kidney disease (CKD), sponsored by Hansoh Pharmaceutical Group. Planned start May 2026; status: not yet recruiting.
02
Drugs
HS-10390
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07555054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07555054.